Processing

Please wait...

Settings

Settings

Goto Application

1. WO2010037760 - COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE

Publication Number WO/2010/037760
Publication Date 08.04.2010
International Application No. PCT/EP2009/062652
International Filing Date 30.09.2009
IPC
C07D 207/08 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
207Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
02with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
04having no double bonds between ring members or between ring members and non-ring members
08with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
C07D 307/12 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
307Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
02not condensed with other rings
04having no double bonds between ring members or between ring members and non-ring members
10with substituted hydrocarbon radicals attached to ring carbon atoms
12Radicals substituted by oxygen atoms
A61K 31/341 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
34having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
341not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/40 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61P 25/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
CPC
C07D 207/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
207Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
02with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
04having no double bonds between ring members or between ring members and non-ring members
08with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
C07D 307/12
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
307Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
02not condensed with other rings
04having no double bonds between ring members or between ring members and non-ring members
10with substituted hydrocarbon radicals attached to ring carbon atoms
12Radicals substituted by oxygen atoms
Applicants
  • GLAXO GROUP LIMITED [GB]/[GB] (AllExceptUS)
  • WARD, Simon, E [GB]/[GB] (UsOnly)
  • BERTHELEME, Nicolas [FR]/[GB] (UsOnly)
Inventors
  • WARD, Simon, E
  • BERTHELEME, Nicolas
Agents
  • SEWELL, Richard, Charles
Priority Data
0818071.302.10.2008GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMPOUNDS WHICH POTENTIATE AMPA RECEPTOR AND USES THEREOF IN MEDICINE
(FR) COMPOSÉS QUI POTENTIALISENT LE RÉCEPTEUR AMPA ET LEURS UTILISATIONS EN MÉDECINE
Abstract
(EN)
A compound of formula (I) and salts thereof are provided wherein Y is defined in the specification. Processes for preparation, pharmaceutical compositions, and uses thereof as a medicament, for example in the treatment of a disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment, are also disclosed.
(FR)
L'invention porte sur un composé de formule (I) et sur des sels de celui-ci, dans laquelle formule Y est tel que défini dans la description. L'invention porte également sur des procédés pour la préparation des composés, sur des compositions pharmaceutiques et sur leurs utilisations comme médicament, par exemple dans le traitement d'une maladie ou affection à médiation par une réduction ou un déséquilibre de la fonction des récepteurs de glutamate, telle que la schizophrénie ou une déficience cognitive.
Latest bibliographic data on file with the International Bureau